Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24943576 | 1.00 | OGA (0.41) | OGACYP2C9CYP2C19ALDH1A1ASGR1 | |
| SCHEMBL10017980 | 1.00 | OGA (0.41) | OGACYP2C9CYP2C19ALDH1A1ASGR1 | |
| SCHEMBL12902089 | 1.00 | OGA (0.41) | OGACYP2C9CYP2C19ALDH1A1ASGR1 | |
| SCHEMBL21966219 | 0.84 | OGA (0.35) | OGACYP2C9CYP2C19ALDH1A1ASGR1 | |
| SCHEMBL22928384 | 0.81 | OGA (0.33) | OGACYP2C9CYP2C19 | |
| SCHEMBL23868171 | 0.79 | HSD11B1 (0.33) | — | |
| SCHEMBL11937054 | 0.78 | CYP2C9 (0.30) | OGACYP2C9CYP2C19 | |
| SCHEMBL403118 | 0.78 | CYP2C9 (0.30) | OGACYP2C9CYP2C19 | |
| SCHEMBL10017978 | 0.73 | — | — | |
| SCHEMBL10023956 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4213884-A1 | MOLECULES WITH SOLUBILITY TAG AND RELATED METHODS | Merck Patent GmbH (DE) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058548-A1 | MOLECULES WITH SOLUBILITY TAG AND RELATED METHODS | MERCK PATENT GMBH (DE) | 2022-03-24 | — | — | WO | disclosed |
| US-9598505-B2 | Silyl-derivatives of polysaccharides | SILDEHA SIXASS S.A. (CH) | 2017-03-21 | — | — | US | disclosed |
| US-9346893-B2 | Process for the preparation of highly O-sulfated, epimerized derivatives of K5 polysacchride and intermediates therein | GLYCORES 2000 S.R.L. (IT) | 2016-05-24 | — | — | US | disclosed |
| US-20140316129-A1 | PROCESS FOR THE PREPARATION OF HIGHLY O-SULFATED, EPIMERIZED DERIVATIVES OF K5 POLYSACCHRIDE AND INTERMEDIATES THEREIN | GLYCORES 2000 S.R.L. (IT) | 2014-10-23 | — | — | US | disclosed |
| US-8513407-B2 | Process for the preparation of N-acyl-(epi)K5-amine-O-sulfate-derivatives and products thus obtained | GLYCORES 2000 S.R.L. (IT) | 2013-08-20 | — | — | US | disclosed |
| US-20120253029-A1 | PROCESS FOR THE PREPARATION OF HIGHLY O-SULFATED EPIMERIZED DERIVATIVES OF K5 POLYSACCHARIDE AND INTERMEDIATES THEREIN | GLYCORES 2000 S.R.L. (IT) | 2012-10-04 | — | — | US | disclosed |
| US-8209131-B2 | Inflammation, allergic diseases, metastatic cancers, pathogen infections; glycosaminoglycan related molecules | CURTIN UNIVERSITY OF TECHNOLOGY (AU) | 2012-06-26 | — | — | US | disclosed |
| US-8193166-B2 | Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation | GLYCORES 2000 S.R.L. (IT) | 2012-06-05 | — | — | US | disclosed |
| US-20110021766-A1 | EPIMERIZED DERIVATIVES OF K5 POLYSACCHARIDE WITH A VERY HIGH DEGREE OF SULFATION | Glycores 2000 S.r.L (IT) | 2011-01-27 | — | — | US | disclosed |
| US-7838644-B2 | Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation | GLYCORES 2000 S.R.L. (IT) | 2010-11-23 | — | — | US | disclosed |
| US-7812151-B2 | Low molecular weight polysaccharides having antithrombotic activity | GLYCORES 2000 S.R.L. (IT) | 2010-10-12 | — | — | US | disclosed |
| US-20090005341-A1 | PROCESS FOR THE PREPARATION OF N-ACYL-(EPI)K5-AMINE-O-SULFATE-DERIVATIVES AND PRODUCTS THUS OBTAINED | GLYCORES 2000 S.R.L. (IT) | 2009-01-01 | — | — | US | disclosed |
| US-20080146522-A1 | Therapeutic Heparins and Their Binding to Interleukins 4 and 5 and Pecam-1 | GLYCAN BIOSCIENCES LLC | 2008-06-19 | — | — | US | disclosed |
| US-20070155694-A1 | Low molecular weight polysaccharides having antithrombotic activity | GLYCORES 2000 S.R.L. (IT) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146522-A1 | Therapeutic Heparins and Their Binding to Interleukins 4 and 5 and Pecam-1 | IL5, CD44, IL4 | OGA 1856/4885CYP2C9 3607/4885CYP2C19 3939/4885 |
| US-20070155694-A1 | Low molecular weight polysaccharides having antithrombotic activity | PLAU, PLG, FASTKD5 | OGA 15/4885CYP2C9 3655/4885CYP2C19 4528/4885 |
| US-20090005341-A1 | PROCESS FOR THE PREPARATION OF N-ACYL-(EPI)K5-AMINE-O-SULFATE-DERIVATIVES AND PRODUCTS THUS OBTAINED | KAT7, KAT5, PIGS | OGA 57/4885CYP2C9 418/4885CYP2C19 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.